JP6839080B2 - 動植物由来ペプチド含有血清カルノシン分解酵素阻害用組成物 - Google Patents
動植物由来ペプチド含有血清カルノシン分解酵素阻害用組成物 Download PDFInfo
- Publication number
- JP6839080B2 JP6839080B2 JP2017528721A JP2017528721A JP6839080B2 JP 6839080 B2 JP6839080 B2 JP 6839080B2 JP 2017528721 A JP2017528721 A JP 2017528721A JP 2017528721 A JP2017528721 A JP 2017528721A JP 6839080 B2 JP6839080 B2 JP 6839080B2
- Authority
- JP
- Japan
- Prior art keywords
- carnosine
- composition
- plant
- peptide
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 178
- 239000000203 mixture Substances 0.000 title claims description 100
- 230000002401 inhibitory effect Effects 0.000 title claims description 65
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 title description 116
- 108010087806 Carnosine Proteins 0.000 title description 115
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 title description 114
- 229940044199 carnosine Drugs 0.000 title description 110
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 title description 108
- 241001465754 Metazoa Species 0.000 title description 94
- 102000004196 processed proteins & peptides Human genes 0.000 title description 50
- 102000004190 Enzymes Human genes 0.000 title description 23
- 108090000790 Enzymes Proteins 0.000 title description 23
- 210000002966 serum Anatomy 0.000 title description 18
- 230000000593 degrading effect Effects 0.000 title description 12
- 102100031006 Beta-Ala-His dipeptidase Human genes 0.000 claims description 115
- 101710192841 Beta-Ala-His dipeptidase Proteins 0.000 claims description 61
- 244000269722 Thea sinensis Species 0.000 claims description 60
- 230000000694 effects Effects 0.000 claims description 50
- 239000000047 product Substances 0.000 claims description 37
- 235000010469 Glycine max Nutrition 0.000 claims description 32
- 230000035882 stress Effects 0.000 claims description 31
- 244000068988 Glycine max Species 0.000 claims description 28
- 102000008186 Collagen Human genes 0.000 claims description 25
- 108010035532 Collagen Proteins 0.000 claims description 25
- 229920001436 collagen Polymers 0.000 claims description 25
- 230000036772 blood pressure Effects 0.000 claims description 19
- 230000005764 inhibitory process Effects 0.000 claims description 19
- 208000024827 Alzheimer disease Diseases 0.000 claims description 17
- 206010020772 Hypertension Diseases 0.000 claims description 16
- 206010012601 diabetes mellitus Diseases 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 230000036542 oxidative stress Effects 0.000 claims description 14
- 206010003805 Autism Diseases 0.000 claims description 13
- 208000020706 Autistic disease Diseases 0.000 claims description 13
- 230000006999 cognitive decline Effects 0.000 claims description 13
- 208000010877 cognitive disease Diseases 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- 108010005094 Advanced Glycation End Products Proteins 0.000 claims description 11
- 230000006872 improvement Effects 0.000 claims description 11
- 206010061218 Inflammation Diseases 0.000 claims description 10
- 230000006870 function Effects 0.000 claims description 10
- 230000004054 inflammatory process Effects 0.000 claims description 10
- 230000036737 immune function Effects 0.000 claims description 9
- 210000004204 blood vessel Anatomy 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 230000003920 cognitive function Effects 0.000 claims description 4
- 208000026278 immune system disease Diseases 0.000 claims description 4
- 102000003850 Dipeptidase 1 Human genes 0.000 claims description 3
- 108090000204 Dipeptidase 1 Proteins 0.000 claims description 3
- 208000035868 Vascular inflammations Diseases 0.000 claims description 3
- 230000036252 glycation Effects 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 description 90
- 235000013616 tea Nutrition 0.000 description 58
- 101000919694 Homo sapiens Beta-Ala-His dipeptidase Proteins 0.000 description 56
- 238000000034 method Methods 0.000 description 36
- 238000011282 treatment Methods 0.000 description 36
- 238000012360 testing method Methods 0.000 description 25
- 229940088598 enzyme Drugs 0.000 description 22
- 235000013361 beverage Nutrition 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 235000013305 food Nutrition 0.000 description 20
- 239000000463 material Substances 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 19
- 238000000354 decomposition reaction Methods 0.000 description 18
- 230000037406 food intake Effects 0.000 description 18
- 238000010438 heat treatment Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 230000009471 action Effects 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 239000007788 liquid Substances 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 108010016626 Dipeptides Proteins 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000006731 degradation reaction Methods 0.000 description 9
- 229960002885 histidine Drugs 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000004531 blood pressure lowering effect Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 230000036651 mood Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 102000004860 Dipeptidases Human genes 0.000 description 4
- 108090001081 Dipeptidases Proteins 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 241000209094 Oryza Species 0.000 description 4
- 235000006468 Thea sinensis Nutrition 0.000 description 4
- 229940000635 beta-alanine Drugs 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 3
- 108010071840 Cytosol nonspecific dipeptidase Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 241000269851 Sarda sarda Species 0.000 description 3
- 244000000231 Sesamum indicum Species 0.000 description 3
- 235000003434 Sesamum indicum Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 244000061456 Solanum tuberosum Species 0.000 description 3
- 235000002595 Solanum tuberosum Nutrition 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 3
- 235000012015 potatoes Nutrition 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 2
- VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002180 anti-stress Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- JUAPMRSLDANLAS-HOTGVXAUSA-N cyclo(L-phenylalanyl-L-phenylalanyl) Chemical compound C([C@@H]1NC([C@@H](NC1=O)CC=1C=CC=CC=1)=O)C1=CC=CC=C1 JUAPMRSLDANLAS-HOTGVXAUSA-N 0.000 description 2
- 108010039669 cyclo(phenylalanyl-phenylalanyl) Proteins 0.000 description 2
- JUAPMRSLDANLAS-UHFFFAOYSA-N cyclo-L-Phe-L-Phe Natural products O=C1NC(CC=2C=CC=CC=2)C(=O)NC1CC1=CC=CC=C1 JUAPMRSLDANLAS-UHFFFAOYSA-N 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000003938 response to stress Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000019710 soybean protein Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229950009811 ubenimex Drugs 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000511343 Chondrostoma nasus Species 0.000 description 1
- 102100031007 Cytosolic non-specific dipeptidase Human genes 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- YIWFXZNIBQBFHR-LURJTMIESA-N Gly-His Chemical compound [NH3+]CC(=O)N[C@H](C([O-])=O)CC1=CN=CN1 YIWFXZNIBQBFHR-LURJTMIESA-N 0.000 description 1
- 101000919690 Homo sapiens Cytosolic non-specific dipeptidase Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010020400 Hostility Diseases 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 125000002066 L-histidyl group Chemical class [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 235000006089 Phaseolus angularis Nutrition 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 240000007098 Vigna angularis Species 0.000 description 1
- 235000010711 Vigna angularis Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002892 effect on hypertension Effects 0.000 description 1
- 230000001814 effect on stress Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 102000049010 human CNDP1 Human genes 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- -1 placenta Proteins 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000004724 ultra fast liquid chromatography Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015142092 | 2015-07-16 | ||
| JP2015142092 | 2015-07-16 | ||
| JPPCT/JP2016/060707 | 2016-03-31 | ||
| PCT/JP2016/060707 WO2017010133A1 (ja) | 2015-07-16 | 2016-03-31 | 動植物由来ペプチド含有血清カルノシン分解酵素阻害用組成物 |
| PCT/JP2016/070798 WO2017010538A1 (ja) | 2015-07-16 | 2016-07-14 | 動植物由来ペプチド含有血清カルノシン分解酵素阻害用組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020180552A Division JP2021020954A (ja) | 2015-07-16 | 2020-10-28 | 動植物由来ペプチド含有血清カルノシン分解酵素阻害用組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2017010538A1 JPWO2017010538A1 (ja) | 2018-04-26 |
| JP6839080B2 true JP6839080B2 (ja) | 2021-03-03 |
Family
ID=57757292
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017528721A Active JP6839080B2 (ja) | 2015-07-16 | 2016-07-14 | 動植物由来ペプチド含有血清カルノシン分解酵素阻害用組成物 |
| JP2020180552A Pending JP2021020954A (ja) | 2015-07-16 | 2020-10-28 | 動植物由来ペプチド含有血清カルノシン分解酵素阻害用組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020180552A Pending JP2021020954A (ja) | 2015-07-16 | 2020-10-28 | 動植物由来ペプチド含有血清カルノシン分解酵素阻害用組成物 |
Country Status (3)
| Country | Link |
|---|---|
| JP (2) | JP6839080B2 (zh) |
| TW (2) | TW201709924A (zh) |
| WO (2) | WO2017010133A1 (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6857683B2 (ja) * | 2018-03-29 | 2021-04-14 | 太陽化学株式会社 | 色調を抑えた茶ペプチド組成物及びその製造方法 |
| JP6598412B1 (ja) * | 2019-06-04 | 2019-10-30 | ゼライス株式会社 | 認知機能改善用食品 |
| TWI747443B (zh) * | 2020-08-14 | 2021-11-21 | 峻億生物科技股份有限公司 | 卵繫帶水解物用於製備改善認知行為組成物的用途 |
| CN116685343A (zh) * | 2020-12-18 | 2023-09-01 | 三得利控股株式会社 | 环二肽在制造抑制认知功能衰退或改善认知功能障碍的试剂中的用途 |
| WO2023120407A1 (ja) * | 2021-12-23 | 2023-06-29 | サントリーホールディングス株式会社 | アミロイドβの産生抑制及び／又は蓄積抑制用組成物 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2811353B2 (ja) * | 1990-07-06 | 1998-10-15 | ゼリア新薬工業株式会社 | 炎症性腸疾患予防・治療剤 |
| JP3962538B2 (ja) * | 2000-09-08 | 2007-08-22 | 三重化糧株式会社 | コラーゲンを主成分とする創傷の皮膚繊維芽細胞遊走・増殖促進剤及びメチシリン耐性黄色ブドウ球菌に作用する抗菌剤 |
| JP3893616B2 (ja) * | 2001-01-16 | 2007-03-14 | 味の素株式会社 | アンジオテンシン変換酵素阻害剤 |
| JP2003081868A (ja) * | 2001-09-12 | 2003-03-19 | Ichimaru Pharcos Co Ltd | ストレス抑制剤 |
| JPWO2004064866A1 (ja) * | 2003-01-20 | 2006-05-18 | イノヴェイティブ ヴィジョン プロダクツ インコーポレーテッド | カルノシナーゼ阻害剤とｌ−カルノシン類との併用および組成物 |
| JP4001239B2 (ja) * | 2004-01-23 | 2007-10-31 | 国立大学法人京都大学 | ダイズ由来ペプチド混合物およびその利用 |
| JP4792563B2 (ja) * | 2005-09-29 | 2011-10-12 | 日本サプリメント株式会社 | 新規なオピオイド活性ペプチド、新規な抗不安ペプチド |
| JP2007238465A (ja) * | 2006-03-06 | 2007-09-20 | Aomori Prefecture | クラゲの酢酸抽出物製造方法およびクラゲコラーゲン由来ペプチド |
| JPWO2007108554A1 (ja) * | 2006-03-17 | 2009-08-06 | 日本ハム株式会社 | 血圧上昇抑制作用を有するペプチド |
| JPWO2007116987A1 (ja) * | 2006-03-31 | 2009-08-20 | 日本ハム株式会社 | 学習機能向上効果及び抗不安効果を有する機能性食品及び薬剤 |
| JP5176964B2 (ja) * | 2006-11-29 | 2013-04-03 | ユーハ味覚糖株式会社 | ジペプチジルペプチダーゼｉｖ阻害剤 |
| JP2009209080A (ja) * | 2008-03-04 | 2009-09-17 | Fuji Oil Co Ltd | アディポネクチン分泌促進組成物 |
| JP5016535B2 (ja) * | 2008-03-27 | 2012-09-05 | 株式会社 資生堂 | 抗老化用食品補助剤および抗老化剤 |
| JP2010013423A (ja) * | 2008-07-07 | 2010-01-21 | Lion Corp | ジペプチジルペプチダーゼ−ｉｖ阻害剤 |
| JP4433082B1 (ja) * | 2008-10-31 | 2010-03-17 | ユーハ味覚糖株式会社 | 神経新生促進剤 |
| CN101744093B (zh) * | 2008-12-17 | 2012-07-25 | 福建福大百特生物科技有限公司 | 一种茶叶蛋白多肽及其制备方法和用途 |
| JP2010248134A (ja) * | 2009-04-16 | 2010-11-04 | Rheology Kino Shokuhin Kenkyusho:Kk | ペプチド組成物 |
| JP5729297B2 (ja) * | 2009-07-13 | 2015-06-03 | 不二製油株式会社 | 経口性抗炎症剤及び経口性抗炎症ペプチド |
| JP2011246425A (ja) * | 2010-05-31 | 2011-12-08 | Fuji Oil Co Ltd | 大豆蛋白質加水分解物含有抗酸化剤 |
| JP2012244930A (ja) * | 2011-05-26 | 2012-12-13 | Ehime Prefecture | かつおの中骨を原料とするコラーゲンペプチドの製造方法 |
| JP6075656B2 (ja) * | 2012-07-25 | 2017-02-08 | 株式会社ニッピ | コラーゲンペプチド組成物の製造方法 |
| JP6291158B2 (ja) * | 2012-11-21 | 2018-03-14 | サントリーホールディングス株式会社 | 抗認知症および学習記憶改善剤 |
| RU2015132368A (ru) * | 2013-02-19 | 2017-03-27 | Данон, С.А. | Функциональные пептиды для расстройств, связанных с ожирением |
| CN103349332A (zh) * | 2013-06-03 | 2013-10-16 | 吴长海 | 一种抗高原反应保健饮料及其制备方法 |
| US20160106130A1 (en) * | 2013-06-10 | 2016-04-21 | Suntory Holdings Limited | Plant extract containing diketopiperazine and method for producing same |
| JP2013241470A (ja) * | 2013-08-30 | 2013-12-05 | Kikkoman Corp | ペプチド含有組成物 |
| JP5646035B1 (ja) * | 2013-11-21 | 2014-12-24 | 三井農林株式会社 | 茶葉由来のタンパク質分解物の製造方法 |
-
2016
- 2016-03-31 WO PCT/JP2016/060707 patent/WO2017010133A1/ja active Application Filing
- 2016-03-31 TW TW105110714A patent/TW201709924A/zh unknown
- 2016-07-14 JP JP2017528721A patent/JP6839080B2/ja active Active
- 2016-07-14 WO PCT/JP2016/070798 patent/WO2017010538A1/ja active Application Filing
- 2016-07-15 TW TW105122443A patent/TW201716068A/zh unknown
-
2020
- 2020-10-28 JP JP2020180552A patent/JP2021020954A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021020954A (ja) | 2021-02-18 |
| JPWO2017010538A1 (ja) | 2018-04-26 |
| WO2017010538A1 (ja) | 2017-01-19 |
| TW201709924A (zh) | 2017-03-16 |
| TW201716068A (zh) | 2017-05-16 |
| WO2017010133A1 (ja) | 2017-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021020954A (ja) | 動植物由来ペプチド含有血清カルノシン分解酵素阻害用組成物 | |
| JP6189994B2 (ja) | ジペプチジルペプチダーゼ−ｉｖ阻害用飲食品組成物 | |
| JP6669750B2 (ja) | 環状ジペプチド含有血清カルノシン分解酵素阻害用組成物 | |
| JP2009269890A (ja) | グルタチオン産生促進剤、グルタチオンの欠乏に起因する疾患の予防・治療剤、飲食品及び飼料 | |
| JPWO2011105435A1 (ja) | 摂食障害治療剤 | |
| JP2015084694A (ja) | ジペプチジルペプチダーゼ−ｉｖ阻害剤 | |
| JP5976004B2 (ja) | ジペプチジルペプチダーゼ−ｉｖ阻害剤 | |
| WO2016133157A1 (ja) | リパーゼ阻害剤 | |
| JP6713991B2 (ja) | アルコール吸収抑制用組成物 | |
| JP5877560B2 (ja) | ジペプチジルペプチダーゼ−ｉｖ阻害剤 | |
| JP6661597B2 (ja) | α−グルコシダーゼ阻害剤 | |
| JP7231313B2 (ja) | 血圧を降下させるための組成物 | |
| JP6083085B2 (ja) | アンジオテンシン変換酵素阻害剤およびその用途 | |
| JP6687619B2 (ja) | メラニン凝集ホルモン受容体拮抗用組成物 | |
| JP6786490B2 (ja) | 抗肥満用組成物 | |
| JP2005006533A (ja) | 機能性食品、その製造方法及び医薬 | |
| JP2001026753A (ja) | 高血圧症予防又は治療用組成物 | |
| JP6770515B2 (ja) | 血圧降下用組成物 | |
| EP4122484A1 (en) | Use of cyclo-hispro (chp) for lowering blood pressure | |
| WO2019168149A1 (ja) | 認知機能を改善するペプチド | |
| JP2023107887A (ja) | 脳血流を増加させるための組成物 | |
| US20080124449A1 (en) | Food for Preventing Life Style-Related Diseases | |
| JP5554175B2 (ja) | メタボリックシンドローム予防又は改善組成物 | |
| JP2023076373A (ja) | アミロイドβ凝集抑制剤とこれを含む医薬組成物および飲食品、ネプリライシン産生促進剤およびγ－セクレターゼ産生抑制剤 | |
| JPWO2006068117A1 (ja) | 腎障害予防剤およびその機能が付与された食品 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190117 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200115 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200311 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200731 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201028 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20201028 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20201105 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20201106 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210113 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210212 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6839080 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |